Detailed Information on Publication Record
2013
Anemia as a predictor of response to antiviral therapy in chronic hepatitis C
URBANEK, P., Michaela KREIDLOVÁ, Ladislav DUŠEK, R. BRUHA, Z. MARECEK et. al.Basic information
Original name
Anemia as a predictor of response to antiviral therapy in chronic hepatitis C
Authors
URBANEK, P. (203 Czech Republic), Michaela KREIDLOVÁ (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic, guarantor, belonging to the institution), R. BRUHA (203 Czech Republic), Z. MARECEK (203 Czech Republic) and J. PETRTYL (203 Czech Republic)
Edition
Bratislava Medical Journal - Bratislavské lékarske listy, BRATISLAVA, Univerzita Komenského, 2013, 0006-9248
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
10600 1.6 Biological sciences
Country of publisher
Slovakia
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 0.446
RIV identification code
RIV/00216224:14110/13:00069218
Organization unit
Faculty of Medicine
UT WoS
000318058700006
Keywords in English
anemia; hepatitis C virus; pegylated interferon; ribavirin
Tags
International impact, Reviewed
Změněno: 9/9/2013 17:19, Soňa Böhmová
Abstract
V originále
Background: The standard therapy for chronic HCV infection is the administration of pegylated interferons in combination with ribavirin. Anemia is a dose-dependent side-effect of ribavirin administration. The degree of anemia could be indicative of the individual exposure to ribavirin. Aims: 1) To evaluate the correlation of HGB level decreases at specified time-points with a sustained virological response during the antiviral treatment. 2) To compare these parameters with the virological predictors for responses. Methods: A retrospective analysis of cohort, which comprised 164 patients treated with standard therapy at a tertiary center in Prague, Czech Republic. Results: We identified several predictive factors for a sustained virological response in females: baseline HGB level <= 140 g/l (p=0.025), maximum drop from baseline >40 g (p=0.039), and a HGB drop in week 4 >30 g (p=0.044). There was only one predictor identified for males: reaching the lowest HGB level after week 19 (p=0.021). The strongest positive predictor of response was a rapid virological response. A low viral load (<600 000 IU/ml) at baseline was not associated with a sustained response in either gender. Conclusions: The parameters of HGB decrease during antiviral treatment are better correlated with a sustained response in females. None of these response predicting parameters was as significant as that of rapid virological response as that of rapid virological response (Tab. 4, Fig. 1, Ref. 15).